Gene Therapy For Eye Pathologies

Last updated:

Abstract:

Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologies of the eye, involving, for example, recombinant viral vectors such as recombinant adeno-associated virus (rAAV) vectors.

Status:
Application
Type:

Utility

Filling date:

2 Apr 2020

Issue date:

12 May 2022